Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
Can-Fite BioPharma announced that the International Journal of Molecular Sciences published a review highlighting the positive effects of its drugs, piclidenoson and namodenoson, on heart diseases. The review, based on over 50 publications, showed that these drugs improved outcomes in pre-clinical studies, such as reducing infarct size and protecting against ischemic injury. Dr. Pnina Fishman noted the drugs' cardio-protective potential and their good safety profile observed in over 1600 patients. Can-Fite is also advancing clinical studies in psoriasis, liver cancer, MASH, and pancreatic cancer.
- Independent scientific review published in a reputable journal highlights positive effects of Can-Fite's drugs on heart diseases.
- Pre-clinical studies show piclidenoson and namodenoson reduce infarct size and protect against ischemic injury.
- Drugs demonstrate beneficial outcomes in various cardiac conditions, supporting their cardio-protective potential.
- Good safety profile observed in over 1600 patients across different conditions.
- The reported benefits are based on pre-clinical studies, not yet confirmed in human clinical trials.
- No new clinical trial results were presented in the PR.
- Ongoing and future clinical studies entail significant costs and inherent risks.
- The success of future trials is uncertain, impacting potential market approval and financial returns.
Insights
The review article published in the International Journal of Molecular Sciences presents a significant body of evidence on the therapeutic benefits of Can-Fite's drugs, piclidenoson and namodenoson, for heart diseases. This adds a new dimension to their previously known anti-inflammatory and oncological applications. From a medical research perspective, the results indicating benefits such as reduction in infarct size and improved contractile function are impressive, given the complexity of treating cardiac conditions. These findings could potentially open up new avenues for these drugs, substantially increasing their market potential. However, it's important to note that these results are from pre-clinical studies. The translation from pre-clinical to clinical success is not guaranteed and more rigorous trials will be needed to confirm these benefits in humans.
Additionally, the integration of cardiac benefits could provide a competitive edge, facilitating multi-indication approvals which can often speed up the regulatory process. Overall, these findings are a promising development, though the real impact will depend on clinical trial results.
Can-Fite BioPharma's announcement regarding the new therapeutic benefits of piclidenoson and namodenoson for heart diseases adds potentially valuable intellectual property to their portfolio. From a financial perspective, this could translate into new revenue streams, assuming the compounds demonstrate efficacy in subsequent clinical trials and gain regulatory approval. The company is already advancing these drugs in other indications such as psoriasis, liver cancer and NASH, which could expedite the time to market for new cardiac indications.
However, investors should be cautious. The costs associated with clinical trials are significant and the company will need substantial funding to advance these studies. Additionally, while positive pre-clinical data is encouraging, failure in later-stage trials could adversely affect the company's valuation. Therefore, while this news is promising, it should be viewed within the context of the high-risk nature of drug development.
RAMAT-GAN,
According to the review, both piclidenoson and namodenoson induced in pre-clinical in vivo studies beneficial outcomes in cardiac ischemia, protection against ischemic/reperfusion injury, reduction in infarct size, improved contractile function against ischemic preconditioning, attenuation of cardiac hypertrophy, fibrosis, and myocardial dysfunction and more.
Can-Fite CSO & Executive Chairperson, Dr. Pnina Fishman commented on these findings, stating, "It is very interesting that our drug candidates have additional well-defined cardio-protective effect and have the potential to positively influence a broad range of heart diseases. In fact, we believe now that this is part of the mechanism contributing to the very good safety profile that has been observed all along the clinical development in more than 1600 patients suffering from psoriasis, liver cancer and MASH”.
Can-Fite continues with its efforts to commence a Phase 3 clinical study in psoriasis, continues to enroll patients in a Phase 3 clinical study in advanced liver cancer as well asa Phase 2b study in MASH while additionally planning to start enrolment for a Phase 2a clinical study in pancreatic cancer in the near term.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529561163/en/
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Source: Can-Fite BioPharma Ltd.
FAQ
What did the scientific review say about Can-Fite’s drugs?
Which journal published the review on Can-Fite’s drugs?
What effects did Can-Fite's drugs have in pre-clinical studies?
What are the next steps for Can-Fite’s drug candidates?
How many patients have been involved in Can-Fite's clinical trials?
